AU2017260323B2 - Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same - Google Patents

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Download PDF

Info

Publication number
AU2017260323B2
AU2017260323B2 AU2017260323A AU2017260323A AU2017260323B2 AU 2017260323 B2 AU2017260323 B2 AU 2017260323B2 AU 2017260323 A AU2017260323 A AU 2017260323A AU 2017260323 A AU2017260323 A AU 2017260323A AU 2017260323 B2 AU2017260323 B2 AU 2017260323B2
Authority
AU
Australia
Prior art keywords
lys
glu
asp
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017260323A
Other languages
English (en)
Other versions
AU2017260323A1 (en
Inventor
Luc Berghman
Lisa Bielke
Leona Nicole Calhoun
Olivia B. Faulkner
Billy Hargis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
University of Arkansas at Little Rock
Original Assignee
Texas A&M University System
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, University of Arkansas at Fayetteville, University of Arkansas at Little Rock filed Critical Texas A&M University System
Publication of AU2017260323A1 publication Critical patent/AU2017260323A1/en
Priority to AU2023255055A priority Critical patent/AU2023255055A1/en
Application granted granted Critical
Publication of AU2017260323B2 publication Critical patent/AU2017260323B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
AU2017260323A 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Ceased AU2017260323B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023255055A AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331044P 2016-05-03 2016-05-03
US62/331,044 2016-05-03
PCT/US2017/030764 WO2017192671A1 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023255055A Division AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Publications (2)

Publication Number Publication Date
AU2017260323A1 AU2017260323A1 (en) 2018-12-20
AU2017260323B2 true AU2017260323B2 (en) 2023-11-16

Family

ID=60203263

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017260323A Ceased AU2017260323B2 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU2023255055A Abandoned AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023255055A Abandoned AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Country Status (12)

Country Link
US (2) US10682398B2 (enExample)
EP (1) EP3452069A4 (enExample)
JP (3) JP7467027B2 (enExample)
KR (2) KR102767638B1 (enExample)
AR (1) AR108688A1 (enExample)
AU (2) AU2017260323B2 (enExample)
BR (1) BR112018072592A2 (enExample)
CA (1) CA3023144A1 (enExample)
MX (1) MX2018013331A (enExample)
SG (1) SG11201809686SA (enExample)
TW (2) TWI843057B (enExample)
WO (1) WO2017192671A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
MX2021012471A (es) 2019-04-11 2022-01-04 Univ Arkansas Aptameros de adn especificos de cd40 como adyuvantes de vacunas.
US11744875B2 (en) 2019-07-12 2023-09-05 Op-T Llc Peptides and methods for treating disease
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
JP2025127116A (ja) 2024-02-20 2025-09-01 セイコーエプソン株式会社 液体吐出装置及び液体吐出装置の制御方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (en) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180280T1 (de) 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
CA2143299A1 (en) 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
AU699291B2 (en) 1995-03-01 1998-11-26 Immunex Corporation Method for stimulating an immune response
MX9709447A (es) 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
JP2001526241A (ja) 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
WO2000014240A2 (en) 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
MXPA00012796A (es) 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
BR0209689A (pt) 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
EP1407004B1 (en) 2001-05-15 2009-08-05 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2470640A1 (en) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Use of hmgb proteins and nucleic acids that code therefor
PL208287B1 (pl) 2001-12-21 2011-04-29 Immunex Corp Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
KR100965026B1 (ko) 2002-02-13 2010-06-21 이뮤놀로지 래보러토리스 인코포레이티드 미생물 감염증을 치료하기 위한 조성물 및 방법
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
AU2003295653B2 (en) 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
CA2546873A1 (en) 2003-11-21 2005-06-02 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005103073A2 (en) 2004-04-27 2005-11-03 Intercell Ag Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006083301A2 (en) 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
EP1765857A2 (en) * 2004-07-02 2007-03-28 Metanomics GmbH Process for the production of fine chemicals
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
JP2009511452A (ja) 2005-10-07 2009-03-19 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
AU2006311752A1 (en) 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP2009535063A (ja) * 2006-05-04 2009-10-01 アブマクシス・インコーポレイテツド 異種間及び複数種提示系
JP5683811B2 (ja) 2006-07-27 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラインフルエンザウイルス様粒子
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
EP2086579A2 (en) 2006-10-27 2009-08-12 Dow AgroSciences LLC Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CA2688548A1 (en) 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP5710482B2 (ja) 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
US8163281B2 (en) 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
NO2525817T3 (enExample) 2010-01-21 2018-01-06
PL2365332T3 (pl) 2010-03-10 2013-10-31 Pasteur Institut HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
BR112012031211A2 (pt) * 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AU2013338153B2 (en) 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
CN105142653B (zh) * 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
CN106535932A (zh) 2014-06-05 2017-03-22 阿肯色大学评议会 抗体引导的疫苗和用于产生快速成熟的免疫应答的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127185A1 (en) * 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Also Published As

Publication number Publication date
TWI843057B (zh) 2024-05-21
EP3452069A4 (en) 2020-02-12
EP3452069A1 (en) 2019-03-13
KR20230070521A (ko) 2023-05-23
KR102767638B1 (ko) 2025-02-20
TW202224701A (zh) 2022-07-01
JP7467027B2 (ja) 2024-04-15
KR20190015712A (ko) 2019-02-14
TW201803590A (zh) 2018-02-01
AU2023255055A1 (en) 2023-11-16
TWI758288B (zh) 2022-03-21
JP2019514971A (ja) 2019-06-06
AR108688A1 (es) 2018-09-19
WO2017192671A1 (en) 2017-11-09
US20200297825A1 (en) 2020-09-24
AU2017260323A1 (en) 2018-12-20
BR112018072592A2 (pt) 2019-04-16
US11382962B2 (en) 2022-07-12
CA3023144A1 (en) 2017-11-09
JP2022040389A (ja) 2022-03-10
US10682398B2 (en) 2020-06-16
US20170319671A1 (en) 2017-11-09
SG11201809686SA (en) 2018-11-29
MX2018013331A (es) 2019-06-10
JP2024023648A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
AU2017205270B2 (en) Therapeutic anticancer neoepitope vaccine
AU2017300965B2 (en) Biofusion proteins as anti-malaria vaccines
AU2020218330B2 (en) Probiotic compositions comprising lactobacillus reuteri strains and methods of use
AU2019336031B2 (en) Chimeric antigen receptor for solid cancer and T cells expressing chimeric antigen receptor
AU2020332969B2 (en) Anti-PD-L1 single domain antibodies
US11382962B2 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU2021228098B2 (en) Soluble ACE2 and fusion protein, and applications thereof
DK2214701T3 (en) CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
JP6532407B2 (ja) アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
AU2022336191A1 (en) Helicobacter pylori composite antigen, antibody, preparation method and use
AU2022207569A9 (en) Stable preparation of human papillomavirus virus-like particle vaccine
CA2066940C (en) Canine coronavirus subunit vaccine
CA2273199A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU2017235361B2 (en) Means and methods for treating HSV
KR101743442B1 (ko) 장독소성 대장균 항원을 발현하는 고스트 살모넬라 변이주를 유효성분으로 포함하는 돼지 부종병의 예방 또는 치료용 백신 조성물
CA2135200C (en) Canine coronavirus s gene and uses therefor
EP0696322A1 (en) METHODS AND COMPOSITIONS FOR $i(SALMONELLA)-BASED VACCINES
CA2435151A1 (en) Method for treating psoriasis
CN103917244B (zh) 用于提高细胞表面的etec cs6抗原呈递的方法及可由其获得的产物
US11497801B2 (en) Compositions and methods of enhancing immune responses
EP4370150A1 (en) Overcoming antibody-interference in avians
CA2365451A1 (en) Nucleic acid molecule comprising a nucleic acid sequence coding for a hemocyanin
KR20230153038A (ko) Rankl 단백질을 코딩하는 유전자를 포함하는 재조합 벡터, 이것을 이용하는 양계용 면역증강용 보조제 및 사료 첨가제
CA2385822A1 (en) Essential gene and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
AU2021230603A9 (en) Live salmonella typhi vectors engineered to express protein antigens and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired